Neurogene (NASDAQ:NGNE) Posts Earnings Results, Misses Expectations By $0.11 EPS

Neurogene (NASDAQ:NGNE) posted its quarterly earnings results on Tuesday. The company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.42) by ($0.11), FiscalAI reports.

Neurogene Stock Performance

NGNE stock opened at $34.54 on Tuesday. Neurogene has a fifty-two week low of $15.93 and a fifty-two week high of $43.66. The business’s 50 day moving average price is $33.34 and its two-hundred day moving average price is $26.46. The company has a market capitalization of $545.73 million, a price-to-earnings ratio of -7.49 and a beta of 1.70.

Insiders Place Their Bets

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,200 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total value of $151,746.00. Following the completion of the transaction, the chief financial officer owned 84,040 shares in the company, valued at approximately $3,036,365.20. This represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 9,600 shares of company stock valued at $339,932 over the last 90 days. 11.68% of the stock is owned by corporate insiders.

Institutional Trading of Neurogene

A number of hedge funds and other institutional investors have recently modified their holdings of NGNE. BNP Paribas Financial Markets lifted its position in Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after acquiring an additional 978 shares during the period. Daiwa Securities Group Inc. purchased a new position in shares of Neurogene during the fourth quarter valued at approximately $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares in the last quarter. Bridgeway Capital Management LLC purchased a new stake in shares of Neurogene in the 3rd quarter worth approximately $187,000. Finally, Brevan Howard Capital Management LP bought a new position in Neurogene during the 3rd quarter valued at approximately $223,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NGNE has been the topic of several recent research reports. UBS Group set a $70.00 price target on Neurogene in a research report on Wednesday, June 3rd. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Neurogene in a research note on Tuesday, June 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a report on Friday, July 17th. Rodman & Renshaw began coverage on shares of Neurogene in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 target price on the stock. Finally, Guggenheim started coverage on shares of Neurogene in a report on Tuesday, April 28th. They set a “buy” rating and a $69.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Neurogene presently has an average rating of “Buy” and an average target price of $84.83.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.